PRO 053
Alternative Names: BMN-053; PRO053; PS-524Latest Information Update: 30 Oct 2021
Price :
$50 *
At a glance
- Originator Prosensa
- Developer BioMarin Nederland
- Class Antisense oligonucleotides
- Mechanism of Action Antisense RNA modulators; Dystrophin expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Duchenne muscular dystrophy
Most Recent Events
- 31 May 2016 Discontinued - Phase-II for Duchenne muscular dystrophy in France, Belgium, United Kingdom, Netherlands, Italy (IV)
- 31 May 2016 Discontinued - Phase-II for Duchenne muscular dystrophy in France, Belgium, United Kingdom, Netherlands, Italy (SC)
- 28 Apr 2015 Prosensa Therapeutics is now called BioMarin Nederland